Wall Street Analysts are Recommending These 5 Stocks in September

4. Moderna, Inc. (NASDAQ:MRNA)

Number of Hedge Fund Holders: 45

Shares of Moderna, Inc. (NASDAQ:MRNA) rose nearly two percent in the extended hours on Wednesday, September 7, 2022, after Deutsche Bank upgraded the Massachusetts-based biotechnology firm from “Hold” to “Buy.”

Deutsche Bank analyst Emmanuel Papadakis was moved by the company’s solid performance in the second quarter. He has a price target of $165 per share for Moderna, Inc. (NASDAQ:MRNA).

Last month, Moderna, Inc. (NASDAQ:MRNA) posted better-than-expected results for Q2. Its adjusted earnings of $5.24 per share easily surpassed the consensus of $4.55 per share. Moreover, the quarterly revenue of $4.7 billion was also better than the expectations of $4.1 billion.